secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRAIL, Inc. (GRAL)
CIK:        0001699031
Form:       8-K
Filed at:   2026-08-05T20:08:32+00:00
Accession:  0001628280-26-053341
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GRAIL Q2 2026 revenue up 26% to $44.7M; Galleri volume up 35% YoY; net loss $110.2M
--------------------------------------------------------------------------------

- Total revenue $44.7M (+26% YoY); Galleri test revenue $42.6M (+24% YoY); test volume >61,000 (+35% YoY).
- Net loss $110.2M, improved $3.7M (3%) YoY; gross loss $12.6M, improved 29%.
- Non-GAAP adjusted gross profit $21.6M (+34% YoY); adjusted EBITDA -$90.3M.
- Completed $110M equity financing with Samsung; PMA submitted, FDA advisory committee expected in fall.
- Presented NHS-Galleri and PATHFINDER 2 results at ASCO 2026, showing consistent performance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1699031/000162828026053341/0001628280-26-053341-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1699031/000162828026053341/gral-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-053341

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer